These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
58 related articles for article (PubMed ID: 34126248)
1. Benefits of Statins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK-9) Inhibitors for Patients with Peripheral Arterial Disease. Paraskevas KI; Mukherjee D; Papas TT Curr Vasc Pharmacol; 2024; 22(1):8-10. PubMed ID: 38037835 [No Abstract] [Full Text] [Related]
2. A therapeutic cooperation by bempedoic acid and proprotein convertase subtilisin/kexin type 9 inhibitors in statin intolerance inherited dyslipidemias. Sbrana F; Bigazzi F; Corciulo C; Dal Pino B Intern Emerg Med; 2024 Jun; ():. PubMed ID: 38872064 [No Abstract] [Full Text] [Related]
3. The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently? Miname MH; Rocha VZ; Santos RD Curr Atheroscler Rep; 2021 Jun; 23(8):40. PubMed ID: 34146170 [TBL] [Abstract][Full Text] [Related]
4. BMJ Rapid Recommendations on use of proprotein convertase subtilisin/kexin 9 inhibitors and ezetimibe to reduce cardiovascular risk. White HD Heart; 2022 Jul; 108(16):1250-1252. PubMed ID: 35508402 [No Abstract] [Full Text] [Related]
5. Clinical characteristics and lipid lowering treatment of patients initiated on proprotein convertase subtilisin-kexin type 9 inhibitors: a nationwide cohort study. Jensen JS; Weeke PE; Bang LE; Høfsten DE; Ripa MS; Schjerning AM; Theilade JE; Køber LV; Gislason GH; Pallisgaard J BMJ Open; 2019 Apr; 9(4):e022702. PubMed ID: 30940751 [TBL] [Abstract][Full Text] [Related]
6. Statins plus ezetimibe in the era of proprotein convertase subtilisin/ kexin type 9 inhibitors. De Luca L; Corsini A; Uguccioni M; Colivicchi F Kardiol Pol; 2020 Sep; 78(9):850-860. PubMed ID: 32716152 [TBL] [Abstract][Full Text] [Related]
8. Trends in Brand-Name Statin Prescriptions Among Physicians Prescribing Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors From 2016 to 2018. Yagi R; Inoue K Endocr Pract; 2021 Sep; 27(9):973-974. PubMed ID: 34126248 [No Abstract] [Full Text] [Related]
9. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications. Navarese EP; Kołodziejczak M; Dimitroulis D; Wolff G; Busch HL; Devito F; Sionis A; Ciccone MM Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):44-53. PubMed ID: 27533061 [TBL] [Abstract][Full Text] [Related]
10. Advances in the field of proprotein convertase subtilisin kexin type 9 inhibitors. Eisen A; Giugliano RP Curr Opin Cardiol; 2016 Nov; 31(6):644-653. PubMed ID: 27661220 [TBL] [Abstract][Full Text] [Related]
11. [Up to date lipid lowering treatment]. Paragh G; Karádi I Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517 [TBL] [Abstract][Full Text] [Related]